References
- Perlroth J, Choi B, Spellberg B. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med Mycol 2007; 45:321 - 46; http://dx.doi.org/10.1080/13693780701218689; PMID: 17510856
- Wang S-J. Candida vaccines development from point view of US patent application. Human Vaccines 2011; 7:1-4.
- Simon BM, Scott CT. Unsettled expectations: how recent patent decisions affect biotech. Nat Biotechnol 2011; 29:229 - 30; http://dx.doi.org/10.1038/nbt.1795; PMID: 21390025
- KSR Int’l Co. v. Teleflex, Inc.: US Supreme Court, 2007.
- Wang S-J. The obviousness rejection as a barrier to biotech patent prosecution. Nat Biotechnol 2009; 27:1125 - 6; http://dx.doi.org/10.1038/nbt1209-1125; PMID: 20010590
- In re Fisher. the United States Court of Appeals for the Federal Circuit 2005.
- Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co.: the United States Court of Appeals for the Federal Circuit 2010.
- Graham v. John Deere Co.: US Supreme Court, 1966.
- CFMT, Inc. v. Yieldup Intern. Corp.: United States Court of Appeals for the Federal Circuit, 2003.
- Gechter v. Davidson. United States Court of Appeals for the Federal Circuit, 1997.
- In re Arkley. the United States Court of Customs and Patent Appeals, 1972.
- Atlas Power Co. v. Ireco Inc.: the United States Court of Appeals for the Federal Circuit, 1999.
- Wang S-J. The state of art patent search with an example of human vaccines. Hum Vaccin 2011; 7:265 - 8; http://dx.doi.org/10.4161/hv.7.2.14004; PMID: 21307657
- Beachcombers v. Wildwood Creative products, Inc.: the United States Court of Appeals for the Federal Circuit 1994.
- In re Berg. the United States Court of Appeals for the Federal Circuit 1998.
- In re Wands. the United States Court of Appeals for the Federal Circuit, 1988.
- Amgen, Inc. v. Chugai Pharmaceutical Co.: the United States Court of Appeals for the Federal Circuit, 1991.
- Toro Co. v. White Consolidated Industries, Inc.: the United States Court of Appeals for the Federal Circuit, 2004.
- Wang S-J. The written description rejection as a barrier to biotech patent prosecution. Hum Vaccin 2011; 7:569 - 73; http://dx.doi.org/10.4161/hv.7.5.14358; PMID: 21552000
- Durham AL. Patent law essentials. Wesport, CT: Quorum Books, 1999.
- Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.: The US Supreme Court, 2002.
- Guidelines for Examination of Patent Applications Under the 35 U.S.C. 112, Written Description Requirement. In: Commerce Do, ed.: Federal Register, 1991:1099.
- McLeod BW, Hayman ML, Purcell AL, Marcus JS, Veitenheimer E. The ‘real world’ utility of miRNA patents: lessons learned from expressed sequence tags. Nat Biotechnol 2011; 29:129 - 33; http://dx.doi.org/10.1038/nbt.1765; PMID: 21301436
- Warner Jenkinson Co., Inc. v. Hilton Davis Chemical Co.: The US Supreme Court, 1997.